Treace Cuts Its Quarterly Loss 23% To $12.6 Million As Revenue Slips 4%

The bunion-surgery device maker narrowed its 2026 revenue range to $206 million to $210 million and now sees a smaller adjusted loss.

Share
Treace Cuts Its Quarterly Loss 23% To $12.6 Million As Revenue Slips 4%

Treace Medical Concepts, which makes instruments, implants and surgical methods for bunion surgery, cut its third-quarter net loss 23% to $12.6 million even as revenue fell 4% to $48.3 million, the company said Friday. It also tightened its 2026 revenue range and lowered its expected adjusted loss.

Cost cuts outrun a sales dip

Revenue was $48.3 million, down from $50.2 million a year earlier. The company blamed a shift toward lower-priced minimally invasive products and fewer bunion procedure kits sold. Excluding sales to stocking distributors, bunion kit volume rose and revenue grew mid-single digits.

Operating expenses fell 10% to $49.9 million from $55.4 million, which the company attributed mainly to targeted expense reductions. The net loss was $0.19 per share, against $0.26 a year earlier. Gross margin was 79.5%, from 79.1%.

Adjusted EBITDA, an earnings measure that strips out items such as stock pay, reached $0.3 million from a loss of $2.6 million. For the first nine months, that measure was still a loss of $8.7 million.

A narrower 2026 forecast

Treace now expects 2026 revenue of $206 million to $210 million, from $204 million to $212 million, a decline of 3% to 1% from 2025. It expects an adjusted EBITDA loss of $1.0 million to $2.0 million, from $3.0 million to $5.0 million. The company reported a $3.9 million adjusted loss for 2025.

The guidance assumes continued case volume growth and improving year-over-year revenue growth rates. Treace also reiterated that it expects cash usage to fall about 50% this year.

Cash and the bunion business

Cash, cash equivalents and marketable securities totaled $39.8 million at September 30. Year-to-date cash usage fell 53%, or $9.7 million, and the credit facility offers up to $115 million more in borrowing, subject to conditions.

Treace's main product is the Lapiplasty 3D Bunion Correction System, sold to surgeons. CEO John T. Treace pointed to "accelerated double-digit case volume growth" and market share gains. About 45% of Lapiplasty surgeon users now use at least one of three bunion systems launched in the third quarter of 2025, up from 40% in the second quarter of 2026.

Management held its conference call at 8:00 a.m. ET Friday to discuss the results.

Sources